Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › Genentech Garners FDA Approval for Tecentriq in Front-Line Lung Cancer Regardless of PD-L1 Status

Genentech Garners FDA Approval for Tecentriq in Front-Line Lung Cancer Regardless of PD-L1 Status

Dec 04, 2019
|
staff reporter

NEW YORK – Genentech announced on Tuesday that its immunotherapy atezolizumab (Tecentriq) was approved by the US Food and Drug Administration as a first-line option for adult patients with metastatic non-squamous non-small cell lung cancer who don't harbor EGFR or ALK genomic tumor aberrations. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Aug
24
Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Sep
10
Featured Webinar

Development of RNA-Based Predictive Response Signatures as Companion Diagnostics

Sponsored by
Genecentric

This webinar, Part 2 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will focus on the development of RNA-based companion diagnostics for oncology.

What's Popular?

In Drug Discovery & Development

  1. Pfizer to Seek Approval for Lorbrena as First-Line Treatment for ALK-Positive Metastatic Lung Cancer

  2. Elios Therapeutics Advancing Personalized Cancer Vaccine in Melanoma After Positive Phase II Data

  3. GeneCentric, Erasmus University to Research RNA Biomarkers, Therapies for Bladder Cancer

  4. T-Cure Bioscience, NHLBI Collaborate to Advance Targeted T-Cell Receptor Therapy

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.